UK Law Lords refuse NICE appeal in Eisai case
This article was originally published in Scrip
The National Institute for health and Clinical Excellencehas been refused permission to argue a case about its economic modelling before the UK House of Lords, the country's highest court of appeal. NICE has now accepted that it must release executable versions of its models to consultees on request.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.